Windlas Biotech Limited (WINDLAS) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.016x

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has a cash flow conversion efficiency ratio of 0.016x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs66.60 Million ≈ $720.25K USD) by net assets (Rs4.16 Billion ≈ $45.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Windlas Biotech Limited balance sheet quality to measure how much of total assets are equity-financed.

Windlas Biotech Limited - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Windlas Biotech Limited to evaluate the quality of earnings relative to operating cash generation.

Windlas Biotech Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Windlas Biotech Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Usun Technology Co Ltd TWO:3498	0.058x
Invivyd Inc. NASDAQ:IVVD	-0.205x
Inesa Intelligent Tech Inc B SHG:900901	-0.009x
Nippon Indosari Corpindo Tbk JK:ROTI	0.047x
RCI Hospitality Holdings Inc NASDAQ:RICK	0.051x
Caisse Régionale de Crédit Agricole du Morbihan PA:CMO	0.004x
Onward Medical N.V. BR:ONWD	-0.366x
GENFIT S.A. ADR/1 EO-25 F:XUPB	N/A

Annual Cash Flow Conversion Efficiency for Windlas Biotech Limited (2018–2025)

The table below shows the annual cash flow conversion efficiency of Windlas Biotech Limited from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Windlas Biotech Limited worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	Rs5.06 Billion ≈ $54.70 Million	Rs681.87 Million ≈ $7.37 Million	0.135x	-44.33%
2024-03-31	Rs4.50 Billion ≈ $48.66 Million	Rs1.09 Billion ≈ $11.78 Million	0.242x	+59.79%
2023-03-31	Rs4.02 Billion ≈ $43.50 Million	Rs609.65 Million ≈ $6.59 Million	0.152x	+555.31%
2022-03-31	Rs3.95 Billion ≈ $42.69 Million	Rs91.30 Million ≈ $987.37K	0.023x	-59.80%
2021-03-31	Rs1.99 Billion ≈ $21.53 Million	Rs114.54 Million ≈ $1.24 Million	0.058x	-51.77%
2020-03-31	Rs2.10 Billion ≈ $22.67 Million	Rs250.06 Million ≈ $2.70 Million	0.119x	+23.77%
2019-03-31	Rs1.94 Billion ≈ $20.94 Million	Rs186.54 Million ≈ $2.02 Million	0.096x	-59.28%
2018-03-31	Rs1.25 Billion ≈ $13.52 Million	Rs295.91 Million ≈ $3.20 Million	0.237x	--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic

Market Cap

$200.70 Million

Rs18.56 Billion INR

Market Cap Rank

#16505 Global

#869 in India

Share Price

Rs880.50

Change (1 day)

+1.03%

52-Week Range

Rs718.35 - Rs1070.80

All Time High

Rs1144.25